Abbvie Inc. · NYSE:ABBV
Abbvie — Q4 2025 Earnings Presentation
4 slides from Abbvie's earnings presentation, Feb 4, 2026
Slide 1: AbbVie Pipeline Update
AbbVie Pipeline Update February 2026
Slide 2: AbbVie R&D Pipeline
AbbVie R&D Pipeline Phase 1 Phase 2 Registrational / Phase 3 Submitted ■ ABBV-243 (7) Autoimmune Diseases ■ ABBV-382 (47) + Skyrizi (IL-23) CD ■ Lutikizumab (IL-1/1) HS ■ Rinvoq (JAK1i) Vitiligo ■ ABBV-319 (CD19 ADC) SLE, Sjorgren’s Disease ■ ABBV-8736 (TREM1) CD ■ Rinvoq (JAK1i) Alopecia Areat
Slide 3: AbbVie - Anticipated Key Pipeline Events
AbbVie - Anticipated Key Pipeline Events 2026 2027 Regulatory Rinvoq Vitiligo Rinvoq Alopecia Areata Epkinly 2L FL (INTL) Skyrizi Crohn’s Disease Subcutaneous Induction Approvals Pivekimab Sunirine BPDCN Epkinly 1L DLBCL Qulipta Migraine Acute Treatment (INTL) Epkinly 2L DLBCL Transplant Ineligible
Slide 4: AbbVie's Partnered Assets
AbbVie’s Partnered Assets • ABBV-461 developed in partnership with Calibr. • ABBV-932 developed in partnership with Gedeon Richter. • ABBV-2001 developed in partnership with IGI. • ABBV-RGX-314 co-developed by REGENXBIO and AbbVie. • Alveltamig developed by Suzhou Zelgen Biopharmaceuticals. AbbVie h